Why carry out this study? |
Responses among biologics for the treatment of moderate-to-severe plaque psoriasis may differ by body region. |
In this post hoc analysis, we assessed and compared the response to ixekizumab (IXE), an interleukin-17A antagonist, versus guselkumab (GUS), an interleukin-23p19 inhibitor, in different body regions of patients enrolled in the IXORA-R study. |
What was learned from the study? |
In both the IXE and GUS cohorts, the speed of response and the cumulative response for Psoriasis Area and Severity Index (PASI) 100 (complete skin clearance) were higher in the head region, followed by the trunk, upper extremities, and lastly lower extremities. |
As compared to GUS, IXE provided a significantly faster response and a significantly higher cumulative response in all body regions. |
Digital Features
Introduction
Methods
Study Design
Patient Population
Outcomes
Statistical Analysis
Results
Demographics and baseline characteristics | Ixekizumab (N = 520) | Guselkumab (N = 507) | Total population, ITT (N = 1027) |
---|---|---|---|
Age, years | 49.0 (13.9) | 49.0 (14.9) | 49.0 (14.4) |
Male, n (%) | 338 (65.0) | 314 (61.9) | 652 (63.5) |
Weight | |||
Weight, kg | 96.6 (24.9) | 94.6 (24.9) | 95.6 (24.9) |
≥ 100 kg, n (%) | 197 (38.0) | 171 (33.7) | 368 (35.9) |
Body Mass Index, kg/m2 | 32.9 (7.9) | 32.8 (7.9) | 32.8 (7.9) |
Duration of PsO since diagnosis, years | 17.5 (13.8) | 16.3 (13.8) | 16.9 (13.8) |
Body Surface Area, % | 24.1 (16.1) | 23.8 (15.4) | 23.9 (15.8) |
Mean PASI score | |||
Body | 19.5 (7.9) | 19.3 (7.1) | 19.4 (7.5) |
Head | 1.6 (1.2) | 1.6 (1.2) | 1.6 (1.2) |
Trunk | 5.3 (3.3) | 5.3 (3.2) | 5.3 (3.2) |
Lower extremities | 8.9 (4.3) | 8.9 (3.9) | 8.9 (4.1) |
Upper extremities | 3.8 (1.9) | 3.6 (1.8) | 3.7 (1.9) |
DLQI total score | 12.8 (6.9) | 13.2 (7.4) | 13.0 (7.1) |
Prior PsO therapy, n (%) | |||
Non-biologic systemic | 170 (32.7) | 141 (27.8) | 311 (30.3) |
Topical therapy | 375 (72.1) | 354 (69.8) | 729 (71.0) |
Phototherapy | 77 (14.8) | 63 (12.4) | 140 (13.6) |
Biologic | 139 (26.7) | 134 (26.4) | 273 (26.6) |